Zacks Investment Research
02 Jul 2026, 15:51 UTC · 3h ago
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
02 Jul 2026, 15:51 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Tango Therapeutics' vopimetostat-daraxonrasib combination showed a 92% objective response rate and 90% six-month progression-free survival in early pancreatic cancer trials. — High clinical efficacy rates in a difficult-to-treat cancer (pancreatic) are strong catalysts for biotech valuation and late-stage development.
+0.80Tango Therapeutics plans to move its MTAP-deleted pancreatic cancer regimen into late-stage development for first-line treatment, pending regulatory feedback. — Transitioning to first-line, late-stage trials significantly increases the probability of commercialization and market capture.
+0.60Tango Therapeutics has established strategic collaborations with Revolution Medicines and Erasca to test vopimetostat in combination with RAS-targeted therapies. — Collaborations reduce cost and risk while expanding the potential therapeutic applications of the primary asset.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
Positive outlook on its precision oncology strategy and strong early clinical signals for vopimetostat.
Positive mention as a central partner in promising combination therapy trials.
Mentioned as a collaborator providing a promising pan-RAS molecular glue.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
